The pharmacological management of inflammatory bowel disease (IBD) over the last two
decades has transitioned from reliance on aminosalycilates, corticosteroids and …

Prior to the biologic era, the medical management of patients with inflammatory bowel
disease (IBD) was dominated by the use of aminosalicylates, corticosteroids, and …

Inflammatory bowel disease (IBD), including Crohn's disease (CD) and Ulcerative Colitis
(UC), are immune mediated conditions associated with progressive damage of the inflamed …

Inflammatory bowel disease (IBD) is a group of chronic disorders of the gastrointestinal tract
comprising Crohn's disease (CD) and ulcerative colitis (UC). Their etiologies are unknown …

Inflammatory bowel disease (IBD) pathogenesis is associated with gut mucosal
inflammation, epithelial damage, and dysbiosis leading to a dysregulated gut mucosal …

Inflammatory bowel diseases (IBDs) are a group of debilitating inflammatory complications
specially inflicting colonic tissue in which full long term remission with current standardized …

Inflammatory bowel disease (IBD) is an immune-mediated inflammatory condition causing
inflammation of gastrointestinal and systemic cells, with an increasing prevalence …

Inflammatory bowel disease (IBD) is a chronic inflammatory condition of gastrointestinal (GI)
tract with dysregulated mucosal immune functions and disturbed commensal ecosystem of …

Advancing knowledge regarding the biology of chronic inflammation has led to the
development of specific biologic therapies that mechanistically target individual …

Inflammatory bowel disease therapy can be considered in several subcategories, and this
review is designed to provide selective updates for some of the most important therapeutic …